Clozapine is an atypical antipsychotic which is described to have higher efficacy among all available antipsychotic medications. Clozapine is reserved especially for resistant schizophrenia due to its side effects. Clozapine-induced metabolic syndrome and hyperglycaemia are common long-term side effects and are responsible for increased mortality in patients with schizophrenia. In this case, a patient with resistant schizophrenia was presented with acute-onset hyperglycaemia and delirium with the use of clozapine within a week. Withdrawal of clozapine in the patient led to the improvement in delirium and hyperglycaemia without the use of any hypoglycaemic agent. This case supports the notion that in certain cases clozapine can induce hyperglycemia through possible direct pathophysiological mechanisms within a shorter time frame.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551436 | PMC |
http://dx.doi.org/10.1136/gpsych-2018-100045 | DOI Listing |
Cureus
December 2024
Department of Psychiatry, Texas Tech University Health Sciences Center, Odessa, USA.
Schizophrenia is a chronic psychiatric disorder with a complex etiology involving genetic, neurobiological, and environmental factors. Many individuals with schizophrenia experience treatment resistance despite advances in pharmacologic and non-pharmacologic interventions. Immune dysregulation, characterized by altered cytokine levels, immune-related gene expression, and neuroinflammation, plays a critical role in schizophrenia's pathogenesis.
View Article and Find Full Text PDFJ Clin Psychopharmacol
January 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Clozapine is effective for treatment-resistant schizophrenia and bipolar disorder but is often discontinued due to adverse effects. This study compared early clozapine discontinuation rates and reasons in patients with mood and psychotic disorders.
Methods: Data from all individuals with mood or psychotic disorders who initiated clozapine for the first time at the inpatient psychiatric unit of Mayo Clinic, Rochester, Minnesota, between 2014 and 2022 were retrospectively analyzed.
Indian J Crit Care Med
January 2025
Resistant Schizophrenia Consultation, Hospital Júlio de Matos, Unidade Local de Saúde São José, Centro Clínico Académico de L, Lisboa, Portugal.
Finsterer J, Marques JG. Continuous Infusion of Propofol or Dexmedetomidine should not be the First Choice to Prevent Postoperative Delirium after Hip Fracture. Indian J Crit Care Med 2025;29(1):86-87.
View Article and Find Full Text PDFEur Psychiatry
January 2025
Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Background: Electroconvulsive therapy (ECT) is a safe and effective treatment for several major psychiatric conditions, including treatment-resistant depression, mania, and schizophrenia; nevertheless, its use remains controversial. Despite its availability in some European countries, ECT is still rarely used in others. This study aims to investigate the experiences and attitudes of early career psychiatrists (ECPs) across Europe towards ECT and to examine how their exposure to ECT influences their perceptions.
View Article and Find Full Text PDFCureus
December 2024
Treatment Resistant Schizophrenia Outpatient Clinic, Júlio de Matos Hospital, São José Local Health Unit, Clinical Academic Center of Lisbon, Lisbon, PRT.
Primary central nervous system lymphoma (PCNSL) is a diffuse, large B-cell lymphoma affecting the brain, spinal cord, leptomeninges, or eyes. A patient with a recurrence of a previous PCNSL manifesting as an isolated vitreoretinal disease without central nervous system (CNS) involvement and a second cerebral recurrence without vitreoretinal involvement has not yet been reported. The patient is an 86-year-old man with PCNSL of the left cerebellum diagnosed at the age of 82 years and treated with suboccipital trepanation and resection of the lesion followed by chemotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!